What is Charm Therapeutics?
Charm Therapeutics operates at the intersection of computational biology and clinical oncology. By utilizing a proprietary AI-driven drug discovery platform, the company aims to solve long-standing challenges in protein-ligand interaction, enabling the rapid identification of novel therapeutic candidates. Its lead program, a next-generation menin inhibitor, is currently positioned to address critical unmet needs in the treatment of acute myeloid leukemia (AML). The company's market position is defined by its ability to integrate deep scientific expertise with scalable machine learning architectures, effectively shortening the timeline from target identification to clinical candidate validation.
How much funding has Charm Therapeutics raised?
Charm Therapeutics has raised a total of $147.3M across 3 funding rounds:
Series A
$50M
Series B
$80M
Stock/Share Issuance
$17.3M
Series A (2022): $50M with participation from OrbiMed, F-Prime Capital Partners, and General Catalyst
Series B (2025): $80M led by New Enterprise Associates, OrbiMed, SR One, and F-Prime Capital
Stock/Share Issuance (2025): $17.3M, investors not publicly disclosed
Key Investors in Charm Therapeutics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with deep expertise in life sciences.
F-Prime Capital
F-Prime Capital is a global venture firm that leverages a team of scientists, doctors, and engineers to invest in transformative healthcare and technology companies.
General Catalyst
General Catalyst is a venture capital firm that partners with founders to build enduring enterprises, providing strategic capital and operational support across diverse sectors including healthcare and enterprise software.
What's next for Charm Therapeutics?
With the recent infusion of capital, Charm Therapeutics is well-positioned to accelerate its clinical development pipeline and expand its computational infrastructure. The strategic focus will likely shift toward advancing its lead menin inhibitor through rigorous clinical trials while simultaneously diversifying its portfolio of oncology assets. As the company scales, it will continue to leverage its AI-driven platform to explore new therapeutic modalities, potentially attracting further institutional backing as it reaches key inflection points in its drug development lifecycle. The firm remains focused on building an enduring enterprise capable of transforming the standard of care for patients with high-risk cancers.
See full Charm Therapeutics company page
